Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Centessa Pharmaceuticals plc CNTA

Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:CNTA)

Fundamentals Snapshot (NDAQ:CNTA)

Current News (NDAQ:CNTA)

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

GlobeNewswire 8 hours ago

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

GlobeNewswire December 10, 2022

Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson

GlobeNewswire November 30, 2022

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses to Contact the Firm

Accesswire November 28, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

Accesswire November 28, 2022

Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate

Business Wire November 28, 2022

Centessa Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 28, 2022 to Discuss Your Rights - CNTA

Newsfile November 28, 2022

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

Newsfile November 28, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Centessa Pharmaceuticals plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2022 - (NASDAQ: CNTA)

PR Newswire November 28, 2022

Opinion & Analysis (NDAQ:CNTA)

No current opinion is available.

Bullboard Posts (NDAQ:CNTA)